Rachel M Squillace

Summary

Affiliation: ARIAD Pharmaceuticals
Country: USA

Publications

  1. Squillace R, Miller D, Wardwell S, Wang F, Clackson T, Rivera V. Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. Int J Oncol. 2012;41:425-32 pubmed publisher
  2. Squillace R, Miller D, Cookson M, Wardwell S, Moran L, Clapham D, et al. Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models. Mol Cancer Ther. 2011;10:1959-68 pubmed publisher
    ..These results underscore the promise of ridaforolimus as a single agent or combination treatment of these tumor types and suggest novel potential predictive biomarkers of sensitivity to an mTOR inhibitor based on cell-cycle status...